Feb 4 (Reuters) – Boston Scientific Corp forecast modest 2026 revenue growth and profit just below Wall Street expectations on Wednesday, overshadowing a strong fourth-quarter performance and sending its shares down more than 11% in premarket trading.
The medical-device maker projected 2026 adjusted earnings per share of $3.43 to $3.49, with the midpoint at $3.46 falling short of the average analyst estimate of $3.47 per share, according to LSEG data.
The subdued outlook comes as the Massachusetts-based company prepares to integrate its $14.5 billion acquisition of Penumbra, announced last month.
The company also expects organic revenue growth of 10% to 11% for 2026, marking a deceleration from the 15.8% organic growth recorded in 2025.
The cautious guidance overshadowed the coronary stents and pacemaker manufacturer’s fourth-quarter results, which surpassed analyst expectations.
The company reported adjusted earnings of 80 cents per share, beating the consensus estimate of 78 cents, while revenue of $5.29 billion edged past forecasts of $5.28 billion.
For the first quarter of 2026, Boston Scientific expects adjusted earnings of 78 cents to 80 cents per share, compared with the analyst consensus of 79 cents.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Tasim Zahid)
